|
Baseline demographic and clinical characteristics of the cohort studied (N = 330 patients). |
|||
| Characteristic |
Not failed (n = 151) |
Failed (n = 179) |
P-value |
|
|
|||
| Gender |
|||
| Male |
84(56) |
93(52) |
0.51 |
| Female |
67(44) |
86(48) |
|
| Age [median years(IQR)] |
34(29–40) |
32(27–38) |
0.15 |
| Socioeconomic status |
|||
| High status |
68(45) |
88(49) |
0.45 |
| Low status |
83(55) |
91(51) |
|
| Baseline CD4 cell count (cells/μl) |
|||
| Median (IQR) |
331(193–467) |
323(208–431) |
0.74 |
| < 200 |
40(27) |
38(21) |
0.28 |
| 200–350 |
41(27) |
62(35) |
|
| > 350 |
70(46) |
79(44) |
|
| WHO stage |
|||
| Stage 1&2 |
74(49) |
83(46) |
0.82 |
| Stage 3 |
59(39) |
71(40) |
|
| Stage 4 |
18(12) |
25(14) |
|
Badri et al. BMC Infectious Diseases 2008 8:89 doi:10.1186/1471-2334-8-89 |
|||